The Goldman Sachs Group Cuts Zoetis (NYSE:ZTS) Price Target to $196.00

Zoetis (NYSE:ZTS - Get Free Report) had its target price decreased by The Goldman Sachs Group from $223.00 to $196.00 in a report released on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. The Goldman Sachs Group's price objective points to a potential upside of 18.11% from the company's current price.

Several other equities analysts have also commented on ZTS. Piper Sandler reissued an "overweight" rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an "overweight" rating on the stock in a report on Tuesday, April 23rd. StockNews.com downgraded Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, April 30th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus target price of $212.38.

Zoetis Stock Down 0.7 %

ZTS traded down $1.12 on Monday, hitting $165.95. 3,080,329 shares of the company were exchanged, compared to its average volume of 3,177,335. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The company has a market cap of $75.72 billion, a price-to-earnings ratio of 31.98, a price-to-earnings-growth ratio of 2.62 and a beta of 0.86. The firm has a 50-day moving average price of $168.25 and a two-hundred day moving average price of $178.92. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. The business's quarterly revenue was up 9.5% compared to the same quarter last year. On average, equities analysts predict that Zoetis will post 5.77 earnings per share for the current year.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 2,209 shares of company stock worth $371,293 over the last three months. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zoetis

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC increased its position in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company's stock worth $25,000 after purchasing an additional 89 shares in the last quarter. Webster Bank N. A. lifted its holdings in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company's stock valued at $29,000 after purchasing an additional 82 shares in the last quarter. Independence Bank of Kentucky lifted its holdings in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company's stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Private Wealth Management Group LLC purchased a new position in Zoetis in the 4th quarter valued at about $33,000. Finally, Ramirez Asset Management Inc. purchased a new position in Zoetis in the 3rd quarter valued at about $35,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.